Dhanvantri Jeevan Rekha Limited (ZDHJERK) Fair Value & Analysis
Healthcare · IN · Market cap ₹108M
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price +38.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹19.00 – ₹35.85 · fair‑value band ₹12.44 – ₹20.74 · the ₹27.75 price screens above the ₹16.59 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dhanvantri Jeevan Rekha Limited (ZDHJERK) currently trades at ₹27.75, while our model-based Fair Value estimate is ₹16.59 — implying the stock looks roughly 40.2% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Dhanvantri Jeevan Rekha Limited generated revenue of ₹259M at a net margin of 1.6%. Revenue grew 24.2% year over year. It earns a return on equity of 3.9%. Net debt stands at ₹8.5M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹12.44 (bear case) to ₹20.74 (bull case); at ₹27.75, the current price sits above that range. The share trades about 23% below its 52-week high and 46% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside — at -40%, ZDHJERK screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Dhanvantri Jeevan Rekha Limited provides medical and health care services in India. The company operates the multi-specialty Dhanvantri hospital in Meerut. Its Dhanvantri Hospital offers diagnostic and therapeutic services, including cardiology, neurology, respiratory medicine, gastroenterology, gastro surgery, neuro surgery, orthopedic surgery, urology, oral and maxillofaccial surgery, oncology, otorhinolaryngology, pathology, rehabilitation program, and other diagnostic services. The company also operates intensive coronary care units and intensive care units. In addition, it offers services for various breast problems, such as mastalgias, mastopathies, breast lumps, and breast cancer, as well as screening for early breast cancers and training for self-examinations. Dhanvantri Jeevan Rekha Limited was founded in 1993 and is based in Meerut, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Dhanvantri Jeevan Rekha Limited reported revenue of ₹259M in FY2026 versus ₹168M in FY2022, a compound +11.4%/yr. Reported net income was ₹4.0M in FY2026, compounding −5.0%/yr from FY2022.
Is ZDHJERK fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Fresenius Medical Care AG FMS | $23.70 | $45.51 | +92% |
| DaVita Inc DVAI34 | R$1,081 | R$207.69 | -81% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,469 | ₹2,967 | -65% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dhanvantri Jeevan Rekha Limited (ZDHJERK) undervalued?
What is the fair value of ZDHJERK?
What is the quality score of ZDHJERK?
What is the revenue of Dhanvantri Jeevan Rekha Limited (ZDHJERK)?
What is the net profit margin of ZDHJERK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.